BCT - ayeyou: "but may be tough to do much in way of share volume without crushing price"
so that was you 2nd half of Thursday then? :)
But as for what's going on, I realised I had missed the 2016-06-30 MD&A (being in the Spanish sun) and had a look at that yesterday, it seems like they are maybe spending time sorting out the irradiation, and can't yet find a clinical site location within their four hour drive time to ship the freshly irradiated BriaVax.Let's hope that is the only problem and that it gets resolved, some extracts and numbers:
At 2016-06-29 for Q3 2016-04-30
... In the latter context, recent activities at the UC Davis GMP facility included experiments to optimize the irradiation conditions to improve the safety of BriaVax™. Such irradiation studies support the anticipated role of the GMP facility as “formulation laboratory” for the clinical trial. In short, BriaCell plans on initiating its clinical trial at a clinical site less than 4 hours of drive- time away from the GMP facility in Sacramento, CA where BriaVax™ would be formulated the day of patient inoculation. Formulation would entail thawing a therapeutic dose of BriaVax™, irradiation to prevent replication (“growth” in the patient) of BriaVax™ once injected into the patient, and resuspension of BriaVax™ in an infusible medium.
Clinical Operations –
Search for Clinical Sites
In preparation of the Company’s planned Phase I/IIa clinical trial, substantial efforts have been made to establish relationships with potential clinical sites and site principal investigators (PIs). Initial attempts were made at hospitals in the Los Angeles, CA area. Recent efforts were dedicated to site selection in an extended San Francisco Bay Area, CA region. Practical considerations included vicinity to the UC Davis GMP facility in Sacramento, i.e., the BriaVax™ manufacturing location, permitting formulation of the BriaVax™ vaccine at the GMP facility the day of patient inoculation and courier-delivery to the treatment site.
As at April 30, 2016, the Company has total assets of $1,519,595 (July 31, 2015 - $1,660,288) and working capital of $1,422,497 (July 31, 2015 – 1,468,408).
[91.3m OS + 19.7m W + 5.2m O =116m FD]
As of June 29, 2016, a total of 23,395,919 shares have been released and a total of 30,887,033 shares remain in escrow. |
